BE1003279A5 - Nouveaux composes pharmacologiquement actifs, leurs procedes de preparation et les compositions en contenant. - Google Patents

Nouveaux composes pharmacologiquement actifs, leurs procedes de preparation et les compositions en contenant. Download PDF

Info

Publication number
BE1003279A5
BE1003279A5 BE8701356A BE8701356A BE1003279A5 BE 1003279 A5 BE1003279 A5 BE 1003279A5 BE 8701356 A BE8701356 A BE 8701356A BE 8701356 A BE8701356 A BE 8701356A BE 1003279 A5 BE1003279 A5 BE 1003279A5
Authority
BE
Belgium
Prior art keywords
pharmacologically active
processes
preparation
same
active compounds
Prior art date
Application number
BE8701356A
Other languages
English (en)
French (fr)
Inventor
Reijo Johannes Baeckstroem
Kalevi Evert Heinola
Erkki Juhani Honkanen
Seppo Kalevi Kaakkola
Pekka Juhani Kairisalo
Inge-Britt Yvonne Linden
Pekka Topias Maennistoe
Erkki Aarne Olavi Nissinen
Pentti Pohto
Aino Kyllikki Pippuri
Jarmo Johan Pystynen
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26158050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE1003279(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FI864875A external-priority patent/FI864875A0/fi
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Application granted granted Critical
Publication of BE1003279A5 publication Critical patent/BE1003279A5/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C205/22—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having one nitro groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C205/23—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having two nitro groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/26—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups and being further substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/34—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/42—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/43—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/562—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with nitrogen as the only hetero atom
    • C07C45/565—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with nitrogen as the only hetero atom by reaction with hexamethylene-tetramine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/24—[b,e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
BE8701356A 1986-11-28 1987-11-27 Nouveaux composes pharmacologiquement actifs, leurs procedes de preparation et les compositions en contenant. BE1003279A5 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI864875A FI864875A0 (fi) 1986-11-28 1986-11-28 Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa.
GB878712437A GB8712437D0 (en) 1986-11-28 1987-05-27 Pharmacologically active compounds

Publications (1)

Publication Number Publication Date
BE1003279A5 true BE1003279A5 (fr) 1992-02-18

Family

ID=26158050

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8701356A BE1003279A5 (fr) 1986-11-28 1987-11-27 Nouveaux composes pharmacologiquement actifs, leurs procedes de preparation et les compositions en contenant.

Country Status (36)

Country Link
US (1) US4963590A (it)
JP (2) JPH085781B2 (it)
CN (1) CN1040062C (it)
AR (1) AR243491A1 (it)
AT (1) AT401053B (it)
AU (1) AU621036B2 (it)
BE (1) BE1003279A5 (it)
BG (1) BG60407B2 (it)
CA (2) CA1289078C (it)
CH (1) CH685436A5 (it)
CS (4) CS277018B6 (it)
DE (2) DE19975025I2 (it)
DK (1) DK175394B1 (it)
EG (1) EG18338A (it)
ES (1) ES2008359A6 (it)
FR (1) FR2607493B1 (it)
GB (1) GB2200109B (it)
GR (1) GR871817B (it)
HK (1) HK75594A (it)
HU (1) HU206073B (it)
IE (1) IE60320B1 (it)
IS (1) IS1753B (it)
IT (1) IT1225762B (it)
LU (1) LU87050A1 (it)
LV (1) LV10236B (it)
MA (1) MA21120A1 (it)
MT (1) MTP1012B (it)
NL (2) NL194821C (it)
NO (1) NO171450C (it)
NZ (1) NZ222729A (it)
PH (1) PH26145A (it)
PL (1) PL152642B1 (it)
PT (1) PT86236B (it)
RU (1) RU2014319C1 (it)
SE (1) SE503434C2 (it)
YU (3) YU213587A (it)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
GB9004348D0 (en) * 1990-02-27 1990-04-25 Orion Yhtymae Oy New use of catechol derivatives and their physiologically acceptable salts and esters
AU632992B2 (en) * 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
MTP1031B (en) * 1987-12-24 1990-10-04 Orion Yhtymae Oy New use of cathecol-o-methyl transferase (comt) inhibitors and their physiologically acceptable salts and esters
US5232923A (en) * 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
DE68917357T2 (de) * 1988-04-28 1995-01-26 Suntory Ltd Derivate der Coffeinsäure und pharmazeutische Zusammensetzungen, die sie enthalten.
IL91382A (en) * 1988-09-01 1995-06-29 Orion Yhtymae Oy Dicitons are converted into alkanyl or ethylmethylene, through their preparation and pharmaceutical preparations containing them
GB9002337D0 (en) * 1990-02-02 1990-04-04 Orion Yhtymae Oy Compounds useful in treating inflammatory bowel disease
US5185370A (en) * 1988-09-01 1993-02-09 Orion-Yhtyma Oy Substituted β-diketones and their use
JPH085780B2 (ja) * 1989-04-28 1996-01-24 呉羽化学工業株式会社 変形性関節症治療剤
GB2238047B (en) * 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
GB9113431D0 (en) * 1991-06-20 1991-08-07 Orion Yhytma Oy Method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
DE69430861T2 (de) * 1993-04-07 2003-01-23 Otsuka Pharmaceutical Co., Ltd. N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
GB9419274D0 (en) * 1994-09-23 1994-11-09 Orion Yhtymae Oy New method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde
GB9510481D0 (en) * 1995-05-24 1995-07-19 Orion Yhtymae Oy New catechol derivatives
GB2316944B (en) * 1995-05-24 1999-01-20 Orion Yhtymae Oy New catechol derivatives
GB9626472D0 (en) 1996-12-20 1997-02-05 Aperia Anita C New use of comt inhibitors
FI981521A0 (fi) 1998-07-01 1998-07-01 Orion Corp Substituoidut beta-diketonit ja niiden käyttö
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI20000635A0 (fi) * 2000-03-17 2000-03-17 Orion Yhtymae Oyj COMT-inhibiittoreiden käyttö analgeettina
US6486210B2 (en) * 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
FI20012242A0 (fi) * 2001-11-19 2001-11-19 Orion Corp Uudet farmaseuttiset yhdisteet
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US8158149B2 (en) 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
WO2005070881A1 (en) * 2003-12-24 2005-08-04 Wockhardt Limited An efficient process for the manufacture of (e)-entacapone polymorphic form a
EP1699753B1 (en) * 2003-12-29 2014-11-26 Suven Life Sciences Limited Improved process for the preparation of entacapone
AU2003292465A1 (en) * 2003-12-29 2005-08-12 Siddiqui Mohammed Jaweed Mukarram Stable polymorphs of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
MY142362A (en) 2004-01-29 2010-11-30 Otsuka Pharma Co Ltd Pharmaceutical composition for promoting angiogenesis
AU2005244167A1 (en) * 2004-05-04 2005-11-24 Beth Israel Deaconess Medical Center Methods and compositions for treatment of preeclampsia
US8138342B2 (en) * 2004-10-12 2012-03-20 High Point Pharmacueticals, LLC 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds
IL169855A (en) * 2005-07-25 2014-05-28 Elta Systems Ltd A system and method for locating a receiver location
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
CA2627306A1 (en) * 2005-11-01 2007-05-10 Transtech Pharma, Inc. Pharmaceutical use of substituted amides
WO2007051811A2 (en) * 2005-11-01 2007-05-10 Transtech Pharma Pharmaceutical use of substituted amides
DE602005017204D1 (de) * 2005-11-09 2009-11-26 Usv Ltd Verfahren zur herstellung von hochreinem (e)-n,n-diethyl-2-cyano-3-(3,4-dihydro-5-nitrophenyl)acrylamid (entacapon)
WO2007077572A1 (en) * 2006-01-02 2007-07-12 Actavis Group Ptc Ehf A process for the preparation of entacapone form-a
ES2382896T3 (es) * 2006-02-06 2012-06-14 Orion Corporation Proceso para la fabricación de entacapona
EP2007722A1 (en) * 2006-03-21 2008-12-31 High Point Pharmaceuticals, LLC Adamantane derivatives for the treatment of the metabolic syndrome
WO2007113845A1 (en) * 2006-04-03 2007-10-11 Alembic Limited A process for the preparation of (e)-2-cyano-3-(3, 4-dihydroxy-5-nitrophenyl)-n, n-diethyl-2-propenamide (entacapone)
CA2648074A1 (en) 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11.beta.-hydroxysteroid dehydrogenase type 1 active compounds
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
WO2007144394A2 (en) * 2006-06-16 2007-12-21 High Point Pharmaceuticals, Llc. Pharmaceutical use of substituted piperidine carboxamides
EP2363123A1 (en) 2006-06-28 2011-09-07 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
US20080004343A1 (en) * 2006-06-29 2008-01-03 Wockhardt Limited Stable polymorphs of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
WO2008006702A1 (en) * 2006-07-13 2008-01-17 High Point Pharmaceuticals, Llc. 11beta-hydroxysteroid dehydrogenase type 1 active compounds
EP1878721A1 (en) * 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2008103202A2 (en) 2006-11-21 2008-08-28 Beth Israel Deaconess Medical Center Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications
US8524746B2 (en) 2007-01-31 2013-09-03 Bial-Portela & Ca., S.A. Dosage regimen for COMT inhibitors
ES2319024B1 (es) 2007-02-13 2009-12-11 Quimica Sintetica, S.A. Procedimiento para la obtencion de entacapona sustancialmente libre de isomero z, sus intermedios de sintesis y nueva forma cristalina.
US8334305B2 (en) * 2007-02-23 2012-12-18 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase
AU2008219326B2 (en) * 2007-02-23 2012-12-13 Vtv Therapeutics Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
US20110003852A1 (en) * 2007-02-23 2011-01-06 Soren Ebdrup N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
US20110003856A1 (en) * 2007-02-23 2011-01-06 Soren Ebdrup N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2008112562A1 (en) 2007-03-09 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
US8153798B2 (en) * 2007-03-09 2012-04-10 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
WO2008119017A1 (en) * 2007-03-28 2008-10-02 High Point Pharmaceuticals, Llc 11beta-hsd1 active compounds
EP1978014A1 (en) * 2007-04-02 2008-10-08 Esteve Quimica, S.A. Process for the preparation of entacapone and intermediates thereof
WO2008127924A1 (en) * 2007-04-11 2008-10-23 High Point Pharmaceuticals, Llc. Novel compounds
WO2008134221A1 (en) * 2007-04-24 2008-11-06 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted amides
WO2008137923A2 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
WO2009084031A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd An improved process for preparation of (2e)-2-cyano-3-(3,4- dihydroxy-5-nitrophenyl)n,n-diethyl-2-propenamide polymorphic form a
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
RU2459812C2 (ru) 2007-12-25 2012-08-27 Киссеи Фармасьютикал Ко., Лтд. Новое производное катехина, фармацевтическая композиция, содержащая производное катехина, применение производного катехина и применение фармацевтической композиции
CA2715802A1 (en) * 2008-02-28 2009-09-03 Bial - Portela & C.A., S.A. Pharmaceutical composition for poorly soluble drugs
AR070907A1 (es) 2008-03-17 2010-05-12 Bial Portela & Ca Sa Formas cristalinas de derivado de nitrocatecol
CA2729405C (en) 2008-07-04 2016-08-02 Kissei Pharmaceutical Co., Ltd. Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
US8927549B2 (en) * 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
ES2915698T3 (es) * 2009-04-01 2022-06-24 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para preparar las mismas
ES2730678T3 (es) 2009-04-01 2019-11-12 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para fabricarlas
CN101817761B (zh) * 2010-01-29 2014-06-25 浙江大学 苯甲酸酯类衍生物及制备方法和应用
CN102816082B (zh) * 2010-01-29 2015-03-11 浙江大学 苯甲酰胺类衍生物及制备方法和应用
BR112012025343A2 (pt) * 2010-04-15 2016-06-28 Merck Patent Gmbh processo para a preparação de hidroquinonas
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
EP2711419A4 (en) * 2011-05-19 2014-12-31 Univ Tokushima INDUCER OF CELL DIFFERENTIATION AND METHOD OF INDUCING DIFFERENTIATION
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
HUE047856T2 (hu) 2011-12-13 2020-05-28 Bial Portela & Ca Sa Kémiai vegyület, amely köztitermékként használható katechol-O-metil-transzferáz inhibitor elõállításához
US20130197090A1 (en) 2012-01-31 2013-08-01 Chelsea Therapeutics, Inc. Postural stability and incident functions in patients
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
EP2847158A4 (en) 2012-05-07 2015-12-30 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
JP6202287B2 (ja) 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド 炎症性腸疾患の治療のための組成物及び方法
JP2015518855A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 粘膜炎の治療のための組成物および方法
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
TWI638802B (zh) * 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
EP3054929B1 (en) 2013-10-07 2020-08-05 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
CN104311426A (zh) * 2014-10-27 2015-01-28 厦门大学 芳香硝基乙烯化合物的新用途
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and pain
US10532976B2 (en) * 2015-06-23 2020-01-14 National Institute Of Biological Sciences, Beijing FTO inhibitors
CN107922316B (zh) * 2015-06-23 2022-04-08 北京生命科学研究所 Fto抑制剂
EA036784B1 (ru) 2016-08-18 2020-12-21 Илько Илач Санайи Ве Тиджарет Аноним Ширкети Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2116579A1 (it) * 1970-12-07 1972-07-13 Reckitt & Colmann Prod Ltd

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB902586A (en) * 1960-01-01 1962-08-01 Shell Res Ltd Herbicidal compositions and novel compounds for use therein
GB1188364A (en) * 1967-05-02 1970-04-15 May & Baker Ltd Quinoline Derivatives
BE759266A (fr) * 1969-11-24 1971-05-24 Hoffmann La Roche Procede pour la preparation de derives de l'indole
CA1190223A (en) * 1977-11-01 1985-07-09 Anthony C. Richardson Substrates for enzymes
JPS5890534A (ja) * 1981-11-25 1983-05-30 Ono Pharmaceut Co Ltd ２−アミノフエノ−ル誘導体、その製造方法およびその誘導体を有効成分として含有する治療剤
ES521195A0 (es) * 1982-04-03 1984-06-01 Beecham Group Plc Un procedimiento para la preparacion de derivados de b-lactama.
SU1424729A3 (ru) * 1983-05-13 1988-09-15 Яманоути Фармасьютикал Ко,Лтд (Фирма) Способ получени производных катехина
FR2557098B1 (fr) * 1983-12-22 1986-06-13 Rhone Poulenc Spec Chim Procede de preparation de bromobenzaldehydes hydroxy et/ou alkoxy substitues
FR2557097B1 (fr) * 1983-12-22 1986-06-13 Rhone Poulenc Spec Chim Procede de preparation de bromobenzaldehydes hydroxy et/ou alkoxy substitues
EP0155335A1 (de) * 1984-03-21 1985-09-25 LUDWIG HEUMANN & CO GMBH Verfahren zur Herstellung von 3,5-Dimethoxy-4-alkoxybenzaldehyden
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
CH676845A5 (it) * 1986-11-07 1991-03-15 Oreal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2116579A1 (it) * 1970-12-07 1972-07-13 Reckitt & Colmann Prod Ltd

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 25, no. 3, mars 1982, pages 258-263; J.W. DALY: "Adenosine receptors: Targets for future drugs" *

Also Published As

Publication number Publication date
NL8702857A (nl) 1988-06-16
EG18338A (en) 1992-09-30
NL194821C (nl) 2003-04-03
JPH085781B2 (ja) 1996-01-24
NZ222729A (en) 1990-04-26
FR2607493B1 (fr) 1994-08-12
BG60407B2 (bg) 1995-02-28
AU8187987A (en) 1988-06-02
IS1753B (is) 2000-07-21
CS844088A3 (en) 1992-05-13
ES2008359A6 (es) 1989-07-16
GB2200109B (en) 1991-07-03
IT8722790A0 (it) 1987-11-27
IS3290A7 (is) 1988-05-29
GB8727854D0 (en) 1987-12-31
IT1225762B (it) 1990-11-26
PL152642B1 (en) 1991-01-31
DE3740383A1 (de) 1988-06-01
NO874966D0 (no) 1987-11-27
MTP1012B (en) 1988-10-18
YU48020B (sh) 1996-10-09
LV10236A (lv) 1994-10-20
FR2607493A1 (fr) 1988-06-03
AR243491A1 (es) 1993-08-31
LU87050A1 (fr) 1988-05-03
PT86236B (pt) 1990-11-07
US4963590A (en) 1990-10-16
NL300136I1 (nl) 2003-12-01
DE3740383C2 (de) 1997-09-25
AU621036B2 (en) 1992-03-05
ATA312987A (de) 1995-10-15
CN87108011A (zh) 1988-06-08
JPS63170311A (ja) 1988-07-14
JP2735834B2 (ja) 1998-04-02
NL194821B (nl) 2002-12-02
HU206073B (en) 1992-08-28
IE873242L (en) 1988-05-28
NO874966L (no) 1988-05-30
DE19975025I2 (de) 2000-08-24
CS276263B6 (en) 1992-05-13
PH26145A (en) 1992-03-18
IE60320B1 (en) 1994-06-29
YU2189A (en) 1989-12-31
YU213587A (en) 1989-06-30
CS843988A3 (en) 1992-01-15
GR871817B (en) 1988-03-24
AT401053B (de) 1996-06-25
CA1289078C (en) 1991-09-17
MA21120A1 (fr) 1988-07-01
YU47790B (sr) 1996-01-09
DK175394B1 (da) 2004-09-20
LV10236B (en) 1995-06-20
NO171450B (no) 1992-12-07
SE8704751D0 (sv) 1987-11-27
PL269091A1 (en) 1988-12-08
HUT45473A (en) 1988-07-28
YU2289A (en) 1989-12-31
CS277018B6 (en) 1992-11-18
SE8704751L (sv) 1988-05-29
GB2200109A (en) 1988-07-27
PT86236A (en) 1987-12-01
NO171450C (no) 1993-03-17
HK75594A (en) 1994-08-12
RU2014319C1 (ru) 1994-06-15
NL300136I2 (nl) 2004-02-02
SE503434C2 (sv) 1996-06-17
DK623087D0 (da) 1987-11-27
CH685436A5 (de) 1995-07-14
CN1040062C (zh) 1998-10-07
CA1334967C (en) 1995-03-28
JPS63150237A (ja) 1988-06-22
DK623087A (da) 1988-05-29

Similar Documents

Publication Publication Date Title
BE1003279A5 (fr) Nouveaux composes pharmacologiquement actifs, leurs procedes de preparation et les compositions en contenant.
BE904226A (fr) Derives 4-substitues d'androst-4-ene-3,17-dione utiles notamment comme inhibiteurs d'aromatase et leur fabrication.
DE3476665D1 (en) 11-beta-aryl-estradienes, their preparation and pharmaceutical compositions containing them
FR2416234A1 (fr) Derives de metronidazole et compositions pharmaceutiques en contenant
ATE168685T1 (de) Aminoheterocyclische derivate als antithrombotische oder antikoagulierende mittel
ES8504211A1 (es) Procedimiento para la preparacion de derivados de oligoglucosido
BE902953A (fr) Derives de 5h-2,3-benzodiazepine procede pour les preparer et compositions pharmaceutiques les contenant
BE903334A (fr) Nouveaux derives naphtaleniques a action retinoique, leurs procedes de preparation et compositions medicamenteuse et cosmetique les contenant
DE3572990D1 (en) Tris-organophosphite compositions having improved hydrolytic stability
BE905109A (fr) Derives de distamycine et leur procede de fabrication.
EP0254744A1 (en) AMINOGLYCOSIDE STEROIDS, THEIR PRODUCTION PROCESS, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2246485A1 (fr) Nouveaux derives de l'indole et de l'indazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2388793A1 (fr) Azetidinyl-acetonitriles et -acetamides, compositions antiarythmiques contenant ces composes et utilisation de ces compositions
BE905110A (fr) Poly-4-aminopyrrole-2-carboxamides et derives, procede pour leur preparation et leurs utilisations therapeutiques.
FR2358382A1 (fr) Nouveaux nonapeptides, leurs procedes de preparation et compositions pharmaceutiques les contenant
FR2354766A1 (fr) Derives n-aminoalkyles d'indole et procedes pour les preparer
IL75891A (en) Antitussive and mucus regulating 2-substituted thiazolidines,their preparation and pharmaceutical compositions containing them
FR2636946A1 (fr) ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
BE904587A (fr) Intermediaires intervenant dans la production d'epipodophyllotoxine et composes apparentes : procedes de preparation et emploi.
BE900899A (fr) Nouveaux composes du cepheme et leurs procedes de preparation.
BE905654A (fr) Derives de la armstrong 2-1,2,4-triazoline-5-one, procede pour leur preparation et leurs utilisations.
FR2450838A1 (fr) Complexes organophosphates de cis-diammineplatine(ii) utiles comme medicaments et compositions pharmaceutiques les contenant
FR2447375A1 (fr) Analogues de la prostaglandine e1 et compositions pharmaceutiques les contenant
TR199700354A2 (xx) Karbohidrat t�revleri.
BE901278A (fr) Derives de 4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine, procedes pour les preparer et medicament les contenant.

Legal Events

Date Code Title Description
CA Change of address of the owner of the patent

Owner name: *ORION CORPORIONINTIE 1, FI-02100 ESPOO

Effective date: 20070830

CH Change of patent owner

Owner name: *ORION CORP

Effective date: 20070830

RE20 Patent expired

Owner name: *ORION CORP

Effective date: 20071127

RE20 Patent expired

Owner name: ORION CORP

Free format text: PRODUCT NAME: ENTACAPONE; REGISTRATION NO/DATE: EU/1/98/082/001 19980916

Effective date: 20121127